Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders [Yahoo! Finance]
Protagenic Therapeutics, Inc. (PTIX)
US:NASDAQ Investor Relations:
protagenic.com/investors
Company Research
Source: Yahoo! Finance
leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The company has reached another milestone by completing three out of five cohorts of healthy volunteers with PT00114, its synthetic version of the stress-regulating peptide TCAP, in a SAD Phase 1 clinical trial. Notably, PT00114 has shown excellent tolerability with no adverse safety findings during these ongoing Phase 1 studies. With promising preclinical efficacy in anxiety, depression, PTSD, and addiction models, PT00114 moves forward in clinical evaluation, representing a step toward potentially transformative therapies. Key Highlights: Safety Validation: Building on the low dose safety validation announced February 13th, PT00114 has now demonstrated safety at a medium dose of 500 micrograms administered subcutaneously in the third of five planned cohorts of subjects in the single dose portion of the Phase I trial. No adverse reactions
Show less
Read more
Impact Snapshot
Event Time:
PTIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTIX alerts
High impacting Protagenic Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTIX
News
- Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit [Yahoo! Finance]Yahoo! Finance
- Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston SummitAccesswire
- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]Yahoo! Finance
- Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 ResultsAccesswire
PTIX
Sec Filings
- 4/24/24 - Form 10-K/A
- 4/1/24 - Form 4
- 4/1/24 - Form 10-K
- PTIX's page on the SEC website